Judge Zahid Quraishi found Novo failed to show irreparable harm, so Lilly's superiority ads stay up while the false advertising suit continues.
Recap by typeshit. Full story at Claims Journal.
Even genuine pens with foreign prescriptions are seized. Lawmakers and a regulatory official now want a review, as Mounjaro costs over three times more in Korea than Japan.
Law360 reports the European patent court could limit the use of divisional patents in a fight involving Novo Nordisk and Ozempic.
Novo had asked the court to halt Lilly advertising it objected to. The judge ruled against the request on October 26, Reuters reports.
The think tank argues regulated compounding beats 'research use only' sellers, noting an FDA panel voted to add six peptides despite staff advising against all seven.
26:19
A personal update from TakingWeightOff on life after stopping tirzepatide, three weeks in, and what caught them off guard.
Records from about 4,900 German practices show over half of patients stayed below 10 mg in their first six months, with 5 mg the most common dose.
Loading…